0000899243-20-013844.txt : 20200521
0000899243-20-013844.hdr.sgml : 20200521
20200521162654
ACCESSION NUMBER: 0000899243-20-013844
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200519
FILED AS OF DATE: 20200521
DATE AS OF CHANGE: 20200521
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Turtle Cameron
CENTRAL INDEX KEY: 0001758363
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38959
FILM NUMBER: 20902204
MAIL ADDRESS:
STREET 1: C/O EIDOS THERAPEUTICS, INC.
STREET 2: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BridgeBio Pharma, Inc.
CENTRAL INDEX KEY: 0001743881
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: (650) 391-9740
MAIL ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
FORMER COMPANY:
FORMER CONFORMED NAME: BridgeBio Pharma LLC
DATE OF NAME CHANGE: 20180618
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-19
0
0001743881
BridgeBio Pharma, Inc.
BBIO
0001758363
Turtle Cameron
C/O BRIDGEBIO PHARMA, INC.
421 KIPLING STREET
PALO ALTO
CA
94301
0
1
0
0
See Remarks
Stock Option (Right to Buy)
1.25
2020-05-19
4
A
0
1082
0.00
A
2020-05-19
2027-08-23
Common Stock
1082
1082
D
Stock Option (Right to Buy)
0.16
2020-05-19
4
A
0
74042
0.00
A
2020-05-19
2029-05-23
Common Stock
74042
74042
D
Stock Option (Right to Buy)
0.34
2020-05-19
4
A
0
49766
0.00
A
2020-05-19
2029-07-14
Common Stock
49766
49766
D
The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in privately-held subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio.
Senior Vice President, Portfolio Management and Corporate Development
/s/ Tara Condon, Attorney-in-Fact
2020-05-21